Who is sponsoring NCT05900921?

NCT05900921 is sponsored by Sichuan University.

What drugs are being tested in NCT05900921?

Interventions in NCT05900921: Trilaciclib, Carboplatin, Paclitaxel, Tislelizumab.

What condition does NCT05900921 study?

NCT05900921 studies Advanced Squamous Non-Small-Cell Lung Cancer.

Is NCT05900921 still recruiting?

NCT05900921 is currently status unknown. Last updated 13 June 2023.

Last reviewed 2023-06-13 · How we verify

NCT05900921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Status unknown Phase 2 Last updated 13 June 2023

What this trial tests

Phase 2 trial testing Trilaciclib in Advanced Squamous Non-Small-Cell Lung Cancer in 132 participants. Status unknown.

Timeline

1 July 2023

Primary endpoint
31 October 2024

31 December 2025

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	132
Start date	1 July 2023
Primary completion	31 October 2024
Estimated completion	31 December 2025

Drugs / interventions tested

Trilaciclib — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →
Tislelizumab (TISLELIZUMAB) — full drug profile →

Conditions studied

Advanced Squamous Non-Small-Cell Lung Cancer — all drugs for Advanced Squamous Non-Small-Cell Lung Cancer →

Sponsor

Sichuan University

Who can join

Adults 18 to 75, any sex, with Advanced Squamous Non-Small-Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the myeloprotective effects of trilaciclib in advanced squamous non-small cell lung cancer patients receiving a combination therapy of chemotherapy(carboplatin+paclitaxel) and immune checkpoint inhibitor (tislelizumab), as well as enhancing antitumor efficacy and possible immunological synergies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Proteomic Analysis Reveals Trilaciclib-Induced Senescence.
Hermosilla-Trespaderne M, Hu-Yang MX, Dannoura A, Frey AM, et al · · 2024 · cited 6× · PMID 38679389 · DOI 10.1016/j.mcpro.2024.100778
Proteomic Analysis Reveals Trilaciclib-Induced Senescence
Hermosilla-Trespaderne M, Hu-Yang MX, Dannoura A, Frey AM, et al · · 2024 · cited 1× · DOI 10.1101/2024.03.12.584620

Verify or expand the search:

Other trials of Trilaciclib

Trials testing the same drug.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT06714266 — Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell · Phase 2 · not yet recruiting
NCT06698965 — Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Tr · Phase 2 · recruiting
NCT06490081 — Trilaciclib Prevents Myelosuppression With Chemoradiotherapy · Phase 2 · recruiting
NCT06370416 — the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib · Phase 2 · enrolling by invitation

Other Sichuan University trials

Trials by the same sponsor.

NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05900921 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan University
Last refreshed: 13 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05900921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing